• Marek Jutel, Ioana Agache, Sergio Bonini, A Wesley Burks, Moises Calderon, Walter Canonica, Linda Cox, Pascal Demoly, Antony J Frew, Robyn O'Hehir, Jörg Kleine-Tebbe, Antonella Muraro, Gideon Lack, Désirée Larenas, Michael Levin, Bryan L Martin, Harald Nelson, Ruby Pawankar, Oliver Pfaar, Ronald van Ree, Hugh Sampson, James L Sublett, Kazunari Sugita, George Du Toit, Thomas Werfel, Roy Gerth van Wijk, Luo Zhang, Mübeccel Akdis, and Cezmi A Akdis.
• Department of Clinical Immunology, Wroclaw Medical University, and "ALL-MED" Medical Research Institute, Wroclaw, Poland. Electronic address: marek.jutel@umed.wroc.pl.
• J. Allergy Clin. Immunol. 2016 Feb 1; 137 (2): 358-68.

AbstractThis article continues the comprehensive international consensus (ICON) statement on allergen immunotherapy (AIT). The initial article also recently appeared in the Journal. The conclusions below focus on key mechanisms of AIT-triggered tolerance, requirements in allergen standardization, AIT cost-effectiveness, and regulatory guidance. Potential barriers to and facilitators of the use of AIT are described in addition to future directions. International allergy specialists representing the European Academy of Allergy and Clinical Immunology; the American Academy of Allergy, Asthma & Immunology; the American College of Allergy, Asthma and Immunology; and the World Allergy Organization critically reviewed the existing literature and prepared this summary of recommendations for best AIT practice. The authors contributed equally and reached consensus on the statements presented herein. Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

26 keywords...

hide…